We recently compiled a list of the 10 Firms End Trading Week Defying Market Bloodbath. In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against the other stocks.
A wave of selling gripped Wall Street this Friday, pushing major indices lower as investors shifted capital towards more attractive investment opportunities.
Ten companies bucked an overall bearish market sentiment, booking significant gains during the last trading day of the week. Let's explore how they managed to buck the trend and what factors contributed to their remarkable performance amidst widespread market uncertainty.
Biotechnology company Geron Corp. (GERN) saw its share price increase by 1.52 percent on Friday to end at $3.35 apiece. Investors resorted to bargain hunting following a drop in its valuation on Thursday.
Albeit booking a lower net loss in the third quarter of the year, the company reported last month that net loss in the first nine months of the year was higher at $149.2 million as compared with the $132.2 million registered year-on-year.
Geron (GERN) recently announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its drug Rytelo for treating specific types of myelodysplastic syndromes. The European Commission will now review this recommendation, with a final decision on market authorization expected in the coming months.
Overall GERN ranks 4th on our list of the firms that ended the trading week defying market bloodbath. While we acknowledge the potential of GERN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than GERN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。